Decoy receptors for TRAIL have shown to play a role in the pathogenesis of tumors as revealed by reports on the detrimental prognostic effect of TRAIL-R3 expression in colorectal cancer [15] or of TRAIL-R4 in breast cancer [16], and by our previously published data on the role of the soluble decoy receptor OPG in determining the resistance to apoptosis in colorectal cancer patients [9]. This evidence concerns the gene TNFRSF10C and breast cancer.